Cary Gunn, PhD, is the President, CEO and a founder of Genalyte. Dr. Gunn currently holds 81 issued US patents, with many more in process. In 2003 he was recognized by MIT Technology Review as a Top Young Innovator, and in 2008 he received the Optical Society of America Adolph Lomb medal and the Berthold-Leibinger Foundation Innovation Prize. Dr. Gunn also co-founded Luxtera where he was responsible for technology development and served as CTO until 2007. Dr. Gunn received his PhD from Caltech in Electrical Engineering. Prior to Caltech, Dr. Gunn was an officer in the US Air Force, responsible for launching GPS satellites and is a graduate of the US Air Force Academy.
Martin Gleeson, PhD, VP, Development and Applications, is a biotech veteran. He brings 25 years of management experience in the research, development and launch of innovative products to serve the life sciences market. Martin came to Genalyte from ZyGem Corp., a successful start-up company focused on sample preparation and genetic analysis, where he was a founding director. Prior to this, he gained a wealth of experience at Invitrogen Corp., where he directed R&D, with a focus on evaluation, integration and productization of technologies, obtained through licensing and acquisition. Earlier in his career Martin held research and research management positions at Ligand Pharmaceuticals and SIBIA (since acquired by Merck). Martin earned his Ph.D. in Genetics from the University of Sheffield, England. He holds more than 30 pending and issued patents and has written more than 25 peer reviewed scientific publications in journals and books.